中國生物科技服務(08037.HK):附屬擬在江蘇設立細胞產業化基地 將獲產業基金等投資1億元
格隆匯9月15日丨中國生物科技服務(08037.HK)宣佈,於2021年9月13日,公司間接附屬隆耀生物與江蘇省如東高新技術產業開發區管委會(“管委會”)及海潤國際併購基金(統稱為“該等投資者”)訂立無法律約束力的合作意向協議,內容有關該等投資者建議投資於公司將由隆耀生物設立的新附屬公司(“該附屬公司”),從事創新免疫細胞治療的研究和開發,並在如東高新技術區為該附屬公司設立研發及生產基地(“該項目”)。
管委會主導的產業基金擬投資人民幣5000萬元於該附屬公司,包括人民幣3000萬元的債權投資(“債權部分”)以及人民幣2000萬元的股權投資。債權部分可由海潤國際併購基金(作為該項目的引薦方)於未來根據當時的估值轉換為該附屬公司的股份,或者由隆耀生物於兩年內於債權部分到期時或之前贖回。
該輪投資的投前估值暫定為人民幣12億元,其將會由該等投資者於盡職調查以及與隆耀生物協商後確定。海潤國際併購基金亦擬投資人民幣5000萬元於該附屬公司作為股權投資。被投資主體將為該附屬公司,其將會根據隆耀生物所授予的特許,在如東高新技術區從事創新免疫細胞治療的研究和開發。
據悉,中國生物科技服務停牌前報1.44港元,總市值13.87億港元。
此外,公司股份由9月15日上午9時正起復牌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.